A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)

Trial Profile

A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs LJPC 501 (Primary)
  • Indications Hypotension
  • Focus Registrational; Therapeutic Use
  • Acronyms ATHOS-3
  • Sponsors La Jolla Pharmaceutical Company
  • Most Recent Events

    • 20 Sep 2017 Results of a pre-specified analysis of this trial were published onlline, according to a La Jolla Pharmaceutical Company.
    • 20 Sep 2017 According to a La Jolla Pharmaceutical Company, data from this trial will be presented at the 30th European Society of Intensive Care Medicine (ESICM) LIVES Annual Congress in September 2017. These results will be reviewed by Marlies Ostermann, M.D.,Ph.D., of Guys and St. Thomas Hospital.
    • 20 Sep 2017 Results of a pre-specified analysis published in the La Jolla Pharmaceutical Company Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top